Tiprogrel

DRUG2 trials

Sponsors

Tianjin Institute of Pharmaceutical Research Co., Ltd

Conditions

Acute Coronary SyndromeIschemic Stroke

Phase 1

Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of Tiprogrel in Healthy Subjects

CompletedNCT06584812

Tianjin Institute of Pharmaceutical Research Co., LtdAcute Coronary Syndrome, Ischemic Stroke

Start: 2024-09-09End: 2024-12-17Updated: 2025-01-06

Phase 2

Study of Tiprogrel in the Treatment of High-risk Patients with Acute Ischemic Cerebrovascular Events (THRIVE).

RecruitingNCT06601127

Tianjin Institute of Pharmaceutical Research Co., LtdIschemic Stroke

Start: 2025-02-21End: 2026-06-01Target: 600Updated: 2025-03-07